Ipsen, the French pharmaceuticals company, yesterday unveiled plans to raise about €400m ($470m) in an initial public offering, which would reduce the stake of the family of founder Henri Beaufour and raise funds for research.
Ipsen, the French pharmaceuticals company, yesterday unveiled plans to raise about €400m ($470m) in an initial public offering, which would reduce the stake of the family of founder Henri Beaufour and raise funds for research.
